{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:25:07Z","timestamp":1787181907749,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biopha.2026.119803","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:26:48Z","timestamp":1785529608000},"page":"119803","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Modelling targeted therapy efficacy in NRAS mutant conjunctival melanoma"],"prefix":"10.1016","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2655-7021","authenticated-orcid":false,"given":"Eetu","family":"V\u00e4lim\u00e4ki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Alanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Suhonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2336-7171","authenticated-orcid":false,"given":"Wilder","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jori","family":"Torkkila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7580-4455","authenticated-orcid":false,"given":"Antti","family":"Kukkula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauliina","family":"Hartiala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Vainio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Sundvall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha K.","family":"Rantala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanne","family":"Erika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anttinen","family":"Mikael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartiala","family":"Pauliina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irjala","family":"Heikki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaakkola","family":"Panu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kauhanen","family":"Saila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komar","family":"Gaber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koskenniemi","family":"Anna-Riina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosola","family":"Sakari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattila","family":"Kalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orte","family":"Katri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4lve","family":"Kristiina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankinen","family":"Matti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvoniemi","family":"Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundvall","family":"Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toriseva","family":"Mervi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torkkila","family":"Jori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vainio","family":"Paula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vihinen","family":"Pia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yl\u00e4-Outinen","family":"Heli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.biopha.2026.119803_bib1","first-page":"3399","article-title":"Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites","volume":"43","author":"Tuomaala","year":"2002","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2026.119803_bib2","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/bjo.2009.157933","article-title":"Time trends in the incidence of conjunctival melanoma in Sweden","volume":"93","author":"Triay","year":"2009","journal-title":"Br. J. Ophthalmol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119803_bib3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/aos.13207","article-title":"Conjunctival malignant melanoma in Denmark. Epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile","volume":"94","author":"Larsen","year":"2016","journal-title":"Acta Ophthalmol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119803_bib4","doi-asserted-by":"crossref","first-page":"515","DOI":"10.21037\/tcr-23-1277","article-title":"Development and validation of a nomogram to predict overall survival of conjunctival melanoma: a population-based study","volume":"13","author":"Peng","year":"2024","journal-title":"Transl. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2026.119803_bib5","first-page":"308","article-title":"[Clinical and pathological features of 26 cases of conjunctival melanoma]","volume":"46","author":"Lin","year":"2010","journal-title":"Zhonghua Yan Ke Za Zhi"},{"issue":"5","key":"10.1016\/j.biopha.2026.119803_bib6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.oftal.2019.01.008","article-title":"A retrospective review of conjunctival melanoma: Presentation, treatment and evolution","volume":"94","author":"Pacheco","year":"2019","journal-title":"Arch. Soc. Esp. Oftalmol. (Engl. Ed. )"},{"issue":"5","key":"10.1016\/j.biopha.2026.119803_bib7","first-page":"503","article-title":"Clinical findings and prognosis of 11 cases of conjunctival malignant melanoma","volume":"116","author":"Kimura","year":"2012","journal-title":"Nippon. Ganka Gakkai Zasshi"},{"issue":"5","key":"10.1016\/j.biopha.2026.119803_bib8","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10384-024-01085-z","article-title":"Clinical features and prognosis of conjunctival melanoma in Japanese patients","volume":"68","author":"Tanabe","year":"2024","journal-title":"Jpn J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119803_bib9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0008-4182(04)80019-X","article-title":"G\u00f3mez-Leal A. Advanced conjunctival melanoma","volume":"39","author":"Rodr\u00edguez-Reyes","year":"2004","journal-title":"Can. J. Ophthalmol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119803_bib10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4274\/tjo.galenos.2020.38096","article-title":"Current Management of Conjunctival Melanoma Part 1: Clinical Features, Diagnosis and Histopathology","volume":"50","author":"Ko\u00e7","year":"2020","journal-title":"Turk. J. Ophthalmol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119803_bib11","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/bjophthalmol-2020-316293","article-title":"American Joint Committee on Cancer Ophthalmic Oncology Task Force. Conjunctival melanoma treatment outcomes in 288 patients: a multicentre international data-sharing study","volume":"105","author":"Jain","year":"2021","journal-title":"Br. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119803_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3341\/kjo.2005.19.2.91","article-title":"Clinical follow-up of conjunctival malignant melanoma","volume":"19","author":"Choi","year":"2005","journal-title":"Korean J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119803_bib13","first-page":"933","article-title":"Anatomoclinical aspects of conjunctival malignant metastatic melanoma","volume":"55","author":"Costea","year":"2014","journal-title":"Rom. J. Morphol. Embryol."},{"key":"10.1016\/j.biopha.2026.119803_bib14","first-page":"64","article-title":"Histologic features of conjunctival melanoma predictive of metastasis and death (an American Ophthalmological thesis)","volume":"110","author":"Esmaeli","year":"2012","journal-title":"Trans. Am. Ophthalmol. Soc."},{"issue":"22","key":"10.1016\/j.biopha.2026.119803_bib15","doi-asserted-by":"crossref","first-page":"6331","DOI":"10.1158\/1078-0432.CCR-13-2368","article-title":"Conjunctival melanomas harbor BRAF and NRAS mutations--response","volume":"19","author":"Griewank","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119803_bib16","first-page":"29","article-title":"Clinical Management of Uveal and Conjunctival Melanoma","volume":"30","author":"Blum","year":"2016","journal-title":"Oncol. (Williston Park."},{"issue":"9","key":"10.1016\/j.biopha.2026.119803_bib17","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41416-018-0046-5","article-title":"NF1 mutations in conjunctival melanoma","volume":"118","author":"Scholz","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2026.119803_bib18","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/aos.13007","article-title":"BRAF mutations in conjunctival melanoma: investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions","volume":"94","author":"Larsen","year":"2016","journal-title":"Acta Ophthalmol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119803_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/tjo.TJO-D-24-00109","article-title":"Current findings of genetic alterations and associated targeted therapies of conjunctival melanocytic neoplasms","volume":"15","author":"Wang","year":"2025","journal-title":"Taiwan. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2026.119803_bib20","article-title":"Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials","volume":"12","author":"Zhou","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119803_bib21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fonc.2019.00232","article-title":"Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma","volume":"9","author":"Rossi","year":"2019","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119803_bib22","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3390\/cancers14061575","article-title":"Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening","volume":"14","author":"Nardou","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119803_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1428152","article-title":"Case report: Conjunctival melanoma treated with relatlimab and nivolumab showing remarkable response","volume":"14","author":"Attrash","year":"2024","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119803_bib24","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3390\/genes14091668","article-title":"Genetic Aspects of Conjunctival Melanoma: A Review","volume":"14","author":"Chang","year":"2023","journal-title":"Genes. (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2026.119803_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40425-019-0555-7","article-title":"Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series","volume":"7","author":"Finger","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119803_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/IOP.0000000000002488","article-title":"Targeted Therapy and Immunotherapy for Advanced Malignant Conjunctival Tumors: Systematic Review","volume":"40","author":"Serbest Ceylanoglu","year":"2024","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"issue":"1","key":"10.1016\/j.biopha.2026.119803_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s40135-025-00334-9","article-title":"Emerging Techniques in the Treatment of Conjunctival Melanoma","volume":"13","author":"Li","year":"2025","journal-title":"Curr. Ophthalmol. Rep."},{"issue":"6","key":"10.1016\/j.biopha.2026.119803_bib28","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nbt.3882","article-title":"Alternative drug sensitivity metrics improve preclinical cancer pharmacogenomics","volume":"35","author":"Hafner","year":"2017","journal-title":"Nat. Biotechnol."},{"issue":"54","key":"10.1016\/j.biopha.2026.119803_bib29","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.21105\/joss.02579","article-title":"Minerva: a light-weight, narrative image browser for multiplexed tissue images","volume":"5","author":"Hoffer","year":"2020","journal-title":"J. Open. Source Softw."},{"issue":"D1","key":"10.1016\/j.biopha.2026.119803_bib30","doi-asserted-by":"crossref","first-page":"D673","DOI":"10.1093\/nar\/gkaf1223","article-title":"The Reactome Knowledgebase 2026","volume":"54","author":"Ragueneau","year":"2026","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"10.1016\/j.biopha.2026.119803_bib31","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic Classification of Cutaneous Melanoma","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119803_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-Seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinforma."},{"issue":"2","key":"10.1016\/j.biopha.2026.119803_bib33","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2020.05.040","article-title":"A Genetic Map of the Response to DNA Damage in Human Cells","volume":"182","author":"Olivieri","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2026.119803_bib34","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.molcel.2018.06.012","article-title":"A Systematic p53 Mutation Library Links Differential Functional Impact to Cancer Mutation Pattern and Evolutionary Conservation","volume":"71","author":"Kotler","year":"2018","journal-title":"Mol. Cell."},{"issue":"1","key":"10.1016\/j.biopha.2026.119803_bib35","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2326-6066.CIR-25-0744","article-title":"RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma","volume":"14","author":"Anastacio Da Costa Carvalho","year":"2026","journal-title":"Cancer Immunol. Res."},{"issue":"14","key":"10.1016\/j.biopha.2026.119803_bib36","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1200\/JCO.22.02018","article-title":"Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study","volume":"41","author":"de Braud","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119803_bib37","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.3390\/cancers13092010","article-title":"A Phase 2 Clinical Trial of Trametinib and Low-Dose Dabrafenib in Patients with Advanced Pretreated NRASQ61R\/K\/L Mutant Melanoma (TraMel-WT)","volume":"13","author":"Awada","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"14","key":"10.1016\/j.biopha.2026.119803_bib38","article-title":"Case report: Complete response of an anaplastic thyroid carcinoma patient with NRAS Q61R\/BRAF D594N mutations to the triplet of dabrafenib, trametinib and PD-1 antibody","volume":"14","author":"Gui","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119803_bib39","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells","volume":"41","author":"Yang","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"24","key":"10.1016\/j.biopha.2026.119803_bib40","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1158\/1078-0432.CCR-24-2713","article-title":"First-in-Human Dose-Escalation Study of the First-in-Class PDE3A-SLFN12 Complex Inducer BAY 2666605 in Patients with Advanced Solid Tumors Coexpressing SLFN12 and PDE3A","volume":"30","author":"Papadopoulos","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119803_bib41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","article-title":"The present and future of the Cancer Dependency Map","volume":"25","author":"Arafeh","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2026.119803_bib42","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1002\/ijc.70191","article-title":"Olaparib for patients with tumors harboring alterations in homologous recombination repair genes: Results from the drug rediscovery protocol","volume":"158","author":"Spiekman","year":"2026","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119803_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2025.1612085","article-title":"Conjunctival melanoma: comprehensive insights into clinical features, genetic alterations, and modern treatment approaches","volume":"31","author":"Ka\u0161telan","year":"2025","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.biopha.2026.119803_bib44","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2022.01.008","article-title":"Genetic characterization of advanced conjunctival melanoma and response to systemic treatment","volume":"166","author":"Lodde","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"11","key":"10.1016\/j.biopha.2026.119803_bib45","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jamaophthalmol.2018.3488","article-title":"Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma","volume":"136","author":"Sagiv","year":"2018","journal-title":"JAMA Ophthalmol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119803_bib46","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40425-019-0555-7","article-title":"Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series","volume":"7","author":"Finger","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.biopha.2026.119803_bib47","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaophthalmol.2017.2279","article-title":"Pembrolizumab for Recurrent Conjunctival Melanoma","volume":"135","author":"Kini","year":"2017","journal-title":"JAMA Ophthalmol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119803_bib48","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1097\/IOP.0000000000001700","article-title":"Immune Checkpoint Inhibitor Therapy as an Eye-Preserving Treatment for Locally Advanced Conjunctival Melanoma","volume":"37","author":"Hong","year":"2021","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"issue":"1","key":"10.1016\/j.biopha.2026.119803_bib49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/01676830.2023.2191273","article-title":"Treatment response and recurrence of conjunctival melanoma with orbital invasion treated with immune checkpoint inhibitors: case report and literature review","volume":"43","author":"Alhammad","year":"2024","journal-title":"Orbit"},{"key":"10.1016\/j.biopha.2026.119803_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1428152","article-title":"Case report: Conjunctival melanoma treated with relatlimab and nivolumab showing remarkable response","volume":"14","author":"Attrash","year":"2024","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119803_bib51","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40257-019-00500-3","article-title":"Conjunctival Melanoma: Current Treatments and Future Options","volume":"21","author":"Grimes","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119803_bib52","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2026.119803_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114008","article-title":"A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma","volume":"202","author":"Wei","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"35","key":"10.1016\/j.biopha.2026.119803_bib54","doi-asserted-by":"crossref","first-page":"58021","DOI":"10.18632\/oncotarget.10770","article-title":"Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy","volume":"8","author":"Cao","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119803_bib55","doi-asserted-by":"crossref","unstructured":"Sai Fung Yeung S.F., Chen J.X., Law C.T.Y., et al. A mutation-resolved therapeutic atlas of NRAS-mutant melanoma reveals genotype-selective response to RAS(ON) inhibition and adaptive STAT3 survival. bioRxiv 2026.02.18.706707; doi: https:\/\/doi.org\/10.64898\/2026.02.18.706707.","DOI":"10.64898\/2026.02.18.706707"},{"key":"10.1016\/j.biopha.2026.119803_bib56","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2022.32","article-title":"Precision oncology using ex vivo technology: a step towards individualised cancer care?","volume":"24","author":"Williams","year":"2022","journal-title":"Expert. Rev. Mol. Med."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:51:40Z","timestamp":1787179900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226008395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":56,"alternative-id":["S0753332226008395"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119803","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modelling targeted therapy efficacy in NRAS mutant conjunctival melanoma","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119803","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119803"}}